USD 12.5 M Funding For The Development Of Intercell’s Vaccine Patch System For Pandemic Influenza From U.S. Department Of Health And Human Services

Intercell AG (VSE: ICLL) announced the execution of a contract modification with the U.S. Department of Health and Human Services (HHS). The agreement commits additional funding of USD 12.5 m for Intercell’s Pandemic Influenza program. Intercell is developing a Pandemic Influenza Vaccine Patch System that includes an immunostimulant patch administered in conjunction with an injected Pandemic Influenza vaccine (manufactured by Solvay Biologicals, B.V.

More: continued here

Filed under: Bird Flu on December 19th, 2008